Stage IIIA Breast Cancer Clinical Trials

1 recruiting

Stage IIIA Breast Cancer Trials at a Glance

18 actively recruiting trials for stage iiia breast cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Houston, Columbus, and Los Angeles. Lead sponsors running stage iiia breast cancer studies include M.D. Anderson Cancer Center, Emory University, and Mayo Clinic.

Browse stage iiia breast cancer trials by phase

Treatments under study

About Stage IIIA Breast Cancer Clinical Trials

Looking for clinical trials for Stage IIIA Breast Cancer? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stage IIIA Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stage IIIA Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 3

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+9 more
Alliance for Clinical Trials in Oncology250 enrolled1 locationNCT05379153
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+2 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Not Applicable

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+20 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT02918474
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Early Phase 1

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+20 more
Ohio State University Comprehensive Cancer Center50 enrolled1 locationNCT05417308
Recruiting
Phase 2

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+12 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT04090567
Recruiting
Phase 1

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+24 more
Emory University18 enrolled4 locationsNCT06324240
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Malignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular Neoplasm+97 more
University of Southern California250 enrolled1 locationNCT07259304
Recruiting
Phase 3

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+2 more
SWOG Cancer Research Network2,400 enrolled963 locationsNCT05929768
Recruiting
Phase 2

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Vandana Abramson51 enrolled1 locationNCT07016399
Recruiting
Not Applicable

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors

Breast CancerAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+18 more
University of Alabama at Birmingham30 enrolled1 locationNCT05452681
Recruiting
Not Applicable

Breast Cancer, Reasoning, and Activity Intervention

Breast CancerBreast NeoplasmsAnatomic Stage II Breast Cancer AJCC v8+3 more
Mayo Clinic160 enrolled1 locationNCT04816006
Recruiting
Not Applicable

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+17 more
University of Alabama at Birmingham40 enrolled1 locationNCT05243056
Recruiting
Phase 1Phase 2

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+17 more
Jonsson Comprehensive Cancer Center18 enrolled1 locationNCT05319873
Recruiting
Phase 2

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Stage III Breast CancerTriple-Negative Breast CarcinomaRecurrent Breast Carcinoma+6 more
Laura Huppert, MD, BA150 enrolled12 locationsNCT03971409
Recruiting
Not Applicable

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+7 more
Emory University27 enrolled3 locationsNCT05368428
Recruiting
Phase 2

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Metastatic Malignant Solid NeoplasmRecurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8+17 more
Rutgers, The State University of New Jersey40 enrolled2 locationsNCT03428802